Other languages Better Therapeutics, Inc.

Equities

BTTX

US08773T1043

Market Closed - OTC Markets Other stock markets 15:35:30 2024-04-29 EDT			5-day change	1st Jan Change
0.012 ^USD	+20.00%		+96.72%	-93.85%

03-21	Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	CI
03-20	Better Therapeutics, Inc.(NasdaqCM:BTTX) dropped from S&P TMI Index	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Better Therapeutics, Inc. Receives Notice of Default from Hercules Capital, Inc	03-21
Sector Update: Health Care Stocks Lower Thursday Afternoon	03-14
Better Therapeutics to Terminate Employees, Explore Strategic Alternatives; Shares Drop Sharply	03-14
Better Therapeutics' Platform Targeting Advanced Liver Disease Receives FDA Breakthrough Device Designation	02-20
Better Therapeutics, Inc. Receives FDA Breakthrough Device Designation for Digital Therapeutic Platform Targeting Advanced Liver Disease	02-20
Better Therapeutics Inc. Announces Publication of Cost-Effectiveness Analysis Demonstrating AspyreRx Is More Effective and Less Costly Than Standard of Care Alone	01-17
Better Therapeutics and Glooko Announce Partnership to Accelerate Adoption of AspyreRx to Treat Type 2 Diabetes in the United States	01-03
Better Therapeutics Seeks FDA Breakthrough Device Designation for Prescription Digital Therapeutics Targeting Liver Diseases	01-02
Better Therapeutics, Inc. Announces Submission for FDA Breakthrough Device Designation for Digital Therapeutic Platform to Treat Liver Disease	01-02
Better Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09
SHARES OF BETTER THERAPEUTICS UP 24.4% AFTER CO ANNOUNCES LAUNCH…	23-10-16
Better Therapeutics, Inc. Announces New Data Highlighting Concurrent Use of AspyreRx and GLP-1 Receptor Agonists to Treat Type 2 Diabetes	23-10-11
Better Therapeutics Says Study of Novel Cognitive Behavioral Therapy Platform Meets Endpoints	23-10-05
Better Therapeutics Completes Enrollment in Study Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes	23-09-28
Better Therapeutics, Inc. Completes Enrollment in Real-World Evidence Program Evaluating Long-term Effectiveness of AspyreRx in Type 2 Diabetes	23-09-28
Better Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09
Insider Buy: Better Therapeutics	23-07-31
Insider Buy: Better Therapeutics	23-07-31
MÄRKTE USA/Wall Street setzt auf niedrige Inflation	23-07-11
Aktien New York: China-Konjunkturmassnahmen stützen den Dow	23-07-11

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Better Therapeutics, Inc.

Equities

BTTX

US08773T1043

Other languages

Filters